Navigation Links
Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
Date:9/3/2008

SB-509 to be Evaluated in Repeat-Dosing Study in Subjects with ALS

RICHMOND, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that it has opened a Phase 2 clinical trial (SB-509-801) to evaluate its drug, SB-509, in subjects with ALS, a progressive, degenerative motor-neuron disease for which there are limited treatment options and no cure.

Sangamo's drug, SB-509, is an injectable formulation of a plasmid encoding a zinc finger DNA-binding protein transcription factor (ZFP TF(TM)) designed to upregulate the expression of the gene encoding vascular endothelial growth factor (VEGF-A). SB-509 is also in three additional Phase 2 clinical trials for diabetic neuropathy and stem cell mobilization. VEGF-A has been shown to have nerve protection properties as well as promoting nerve, blood vessel and muscle growth.

In ALS, the motor nerves comprised of nerve cells in the brain and spinal cord that control the body's voluntary muscles, gradually degenerate. As the nerve cells begin to die, the muscles weaken and shrink. As the disease progresses, patients gradually lose the use of their limb and neck muscles, ultimately becoming paralyzed and unable to breathe without assistance. Fifty percent of patients with ALS die within three to five years of diagnosis. Currently, there is only one approved drug for ALS; Riluzole has been demonstrated to slow the progression of this debilitating disease with only modest clinical benefit, extending the survival of ALS patients by approximately three months.

"Initiation of a Phase 2 clinical study of SB-509 in subjects with a motor neuron and muscle disease such as ALS is an obvious next step in the evaluation of this novel therapeutic," stated Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "The drug is designed to activate the expression of the subject's own VEGF-A gene. There is mounting pre-clinical and clinical evidence to support a correlation between reduced VEGF-A levels and progression of this life-threatening disease. Our Phase 1 clinical studies of SB-509 in diabetic neuropathy have shown that the drug is well tolerated. Data from this clinical study and pre-clinical studies in animal models of nerve damage reveal positive effects of SB-509 on motor nerve function and muscle composition. Similar effects on motor nerves and muscles in these patients may slow the progression of ALS by preserving nerve function and improving muscle fiber composition and strength."

The Phase 2 trial (SB-509-801) is a randomized repeat-dosing, open-label, multi-center study designed to evaluate the effect of intramuscular administration of SB-509 on the progression of the disease in subjects with ALS, as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) a validated rating instrument for monitoring the progression of disability in patients with ALS. Efficacy of SB-509 will be evaluated by comparing the rate of ALS disease progression in subjects treated with SB-509 in this study to historical placebo controls. In addition to gathering data on safety and tolerability of SB-509 in subjects with ALS, data will be collected to evaluate the effect of SB-509 on additional clinical measures. These measures include Forced Vital Capacity (FVC), a test of lung function; Neurophysiologic Index (NI), a measure of neurologic impairment; Manual Muscle Test (MMT), a test of muscle strength; and survival. Finally, the study will also evaluate stem cell mobilization in subjects with ALS receiving SB-509.

"We are pleased to meet our goal of beginning a Phase 2 clinical trial in ALS this year and are very excited to begin these proof of principle studies," said Edward Lanphier, Sangamo's president and CEO. "VEGF has been demonstrated to have a fundamental role in the growth and health of blood vessels, nerves and muscle and we believe that our approach of using a ZFP TF to stimulate the expression of all of the natural forms of a subject's own VEGF-A gene may have potential therapeutic benefit for a variety of neurodegenerative conditions including ALS."

About the Study, SB-509-801

A total of 40 subjects with ALS will be enrolled in this trial and randomized into one of two treatment cohorts. The first cohort of 35 subjects will receive 60 mg of SB-509 in a divided dose into muscles in the arm, leg, and along the spine on both sides of the body. A second cohort of 5 subjects will receive 60 mg of SB-509 in a divided dose into the muscles in the lower limb in both legs. Each subject will receive a total of two treatments of 60 mg of SB-509 intramuscularly three months apart on Day 0 and Day 90. The study will be carried out over 11 months, including 2 months for screening, 3 months for two study treatments, and 6 months of follow-up after administration of the final dose. Individuals interested in participating in this trial should visit http://www.clinicaltrials.gov/ or http://www.alsa.org

About Amyotrophic Lateral Sclerosis (ALS)

More than 30,000 Americans have ALS, according to the ALS Association, a nonprofit organization that supports ALS research and public and patient education about the disease. 3,000 to 5,000 new cases of the disease are diagnosed every year. Men and women of all ethnic and racial groups are equally affected, usually between the ages of 40 and 70. The disease attacks the motor nerves, nerve cells in the brain and spinal cord that control the body's voluntary muscles. As the motor nerves begin to die, the muscles weaken and shrink. Early symptoms of ALS may include unusual tiredness and clumsiness, muscle weakness, slurred speech, and difficulty swallowing. As the disease progresses, patients gradually lose the use of their hands, arms, legs, and neck muscles, ultimately becoming paralyzed. They can speak and swallow only with great difficulty. About half of people with ALS die within three to five years of diagnosis.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Other therapeutic development programs are focused on cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to clinical trials of SB-509 and the potential for further study and development of SB-509, research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the initiation and completion of stages of the SB-509 clinical trials, whether the SB-509 clinical trials will validate and support safety, tolerability and efficacy of SB-509, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See Sangamo's SEC filings, and in particular, the risk factors described in its Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
7. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
11. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... The global  reprocessed medical devices ... 2022, according to a new study by Grand View ... with the lack of centralized support for waste disposal ... demand for reprocessed medical devices market. Additionally, the long-term ... of the original device is the high impact rendering ...
(Date:5/20/2016)... 2016 ReportsnReports.com adds Global ... Devices of its online business intelligence library. This ... current state of the Titrator industry. The report ... definitions, classifications, Specifications, applications and industry chain structure. ... Raw Material Suppliers, Equipment Suppliers, Manufacturing Cost Structure, ...
(Date:5/20/2016)... India , May 20, 2016 ... growth driver is the increasing demand for affordable healthcare solutions ... been steadily on the rise. In countries like the US, ... decade. In the US, the consumer price index inflation rate ... healthcare inflation rate moved up to 3.62% during the same ...
Breaking Medicine Technology:
(Date:5/23/2016)... , ... May 23, 2016 , ... NYDNRehab, a New ... program for athletes. This is the first time this type of technology, which was ... made available to the public in New York. , With over 10 million ...
(Date:5/23/2016)... Diego, CA (PRWEB) , ... May 23, 2016 , ... ... various regulatory subjects will host medical device summit on September 15 and 16, ... world’s leading experts and former FDA office bearers will be one of the largest ...
(Date:5/23/2016)... (PRWEB) , ... May 23, ... ... and security executive networking and relationship-marketing firm, announced today that nominations will ... Information Security Executive® (ISE®) Northeast Awards. , Awards include the Information Security ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... education worldwide for people who are blind or visually impaired, announces the election ... retiring President Charles E. Young. Hadley’s Board of Trustees retained Morris & Berger, ...
(Date:5/23/2016)... ... 2016 , ... Octo Consulting Group, a leading provider of innovative information technology ... they have recently won two awards from AFCEA International. Octo was selected as ... Additionally, Octo VP of Civilian Affairs, Naina Leo, was named a winner of the ...
Breaking Medicine News(10 mins):